BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Drug Development

  Roivant to Shutter MDS-Focused ‘Vant’ After Disappointing Phase I/II Trial Results

  Roivant Sciences will wind down operations for Hemavant, which was formed two years ago to advance RVT-2001 as a potential first-in-class treatment for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes.

  February 14, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  European-Based VC Earlybird Health Closes $186M Fund

  The venture capital fund will finance companies in Europe who are in the early stages of development with the goal of advancing them to regulatory approval and commercialization.

  February 14, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  FDA

  FDA Approves Ipsen’s Onivyde as First-Line Treatment in Metastatic Pancreatic Cancer

  Approved in combination with three chemotherapies, Onivyde is the first new frontline treatment option in more than 10 years for adults living with metastatic pancreatic adenocarcinoma.

  February 14, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  FTC and HHS Launch Probe of Ongoing Generic Drug Shortages

  The Federal Trade Commission and Department of Health and Human Services on Wednesday said they are investigating group purchasing organizations and drug wholesalers’ possible involvement.

  February 14, 2024

   · 

  1 min read

   · 

  Tyler Patchen
• 

  Policy

  DOJ, SEC Subpoenas Add to Biogen’s Compounding Problems

  The Department of Justice is seeking more information regarding Biogen’s overseas operations, while the Securities and Exchange Commission is looking into the launch of the now-defunct Alzheimer’s disease therapy Aduhelm.

  February 14, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  How Immigration Policy Changes Can Affect Biopharma Hiring

  Changes to U.S. visa policy in 2022 reportedly increased the number of foreign-born STEM workers, but some say more needs to be done to ensure companies can hire the best talent.

  February 14, 2024

   · 

  6 min read

   · 

  Nadia Bey
• 

  Policy

  FDA Pushes Back PDUFA Data for Rocket’s Gene Therapy for Rare Blood Disorder

  Citing the need for more time to review additional Chemistry, Manufacturing and Controls information, the FDA has extended its target action date for Rocket Pharmaceuticals’ investigational gene therapy by three months.

  February 14, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Job Trends

  5 Companies Hiring Scientists Now

  If you’re a researcher looking for your next challenge, check out these companies with current openings on BioSpace.

  February 14, 2024

   · 

  1 min read

   · 

  BioSpace Editorial Staff
• 

  BioForest

  ADC-Focused ProfoundBio Raises $112M in Oversubscribed Series B

  The latest round of funding for Seattle-based ProfoundBio will go towards advancing its one preclinical and three clinical antibody-drug conjugate candidates.

  February 14, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Drug Delivery

  Eyes on the prize: Novo buys Catalent

  This week, Greg, Heather and Tyler discuss reaction to ⁠Novo Nordisk’s purchase of Catalent⁠ and speculate on what that means for existing manufacturing contracts, customers and consequences with ⁠regulators⁠.

  February 14, 2024

   · 

  1 min read

   · 

  Greg Slabodkin, Heather McKenzie, Tyler Patchen